SCHEMBL1979376

SCHEMBL1979376

Cc1ccc(S(=O)(=O)Oc2ccc(Br)nc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
CA2 P00918 3/20 0.42
ALDH1A1 P00352 3/20 0.42
CA12 O43570 2/20 0.42
MAPT P10636 2/20 0.42
HTT P42858 2/20 0.42
PPARG P37231 1/20 0.42
ESR1 P03372 1/20 0.41
GAA P10253 1/20 0.41
ESR2 Q92731 1/20 0.41
ENPP3 O14638 3/20 0.41
ENPP1 P22413 3/20 0.41
ENPP2 Q13822 3/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2011197 0.93 MEN1 (0.42) MEN1KMT2AKEAP1NFE2L2CA2
SCHEMBL10684102 0.84 MEN1 (0.49) MEN1KMT2AKEAP1NFE2L2CA2
SCHEMBL9852204 0.79 MEN1 (0.60) MEN1KMT2ACA2ALDH1A1CA12
SCHEMBL4126086 0.79 MEN1 (0.60) MEN1KMT2ACA2ALDH1A1CA12
SCHEMBL18179825 0.79 MEN1 (0.60) MEN1KMT2ACA2ALDH1A1CA12
SCHEMBL5255332 0.79 KMT2A (0.45) MEN1KMT2AKEAP1NFE2L2CA2
SCHEMBL31637724 0.78 CA12 (0.49) ALDH1A1CA12HPGD
SCHEMBL4195648 0.78 MEN1 (0.53) MEN1KMT2ACA2ALDH1A1CA12
SCHEMBL18359536 0.78 MEN1 (0.53) MEN1KMT2ACA2ALDH1A1CA12
SCHEMBL10678544 0.78 KMT2A (0.47) MEN1KMT2AKEAP1NFE2L2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108586369-B Process for producing phenyltriazine compound and process for producing phenylpyridine compound 中国科学院长春应用化学研究所 2021-08-17 CN disclosed
EP-3407974-A1 AMLEXANOX ANALOGS The Regents Of The University Of Michigan (US) 2018-12-05 EP disclosed
US-20170217980-A1 AMLEXANOX ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-08-03 US disclosed
US-20170217980-A1 AMLEXANOX ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-08-03 US disclosed
US-20170217980-A1 AMLEXANOX ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2017-08-03 US disclosed
WO-2017132538-A1 AMLEXANOX ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-08-03 WO disclosed
WO-2017132538-A1 AMLEXANOX ANALOGS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-08-03 WO disclosed
WO-2016126085-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 비욘드바이오주식회사 2016-08-11 WO disclosed
WO-2011072064-A1 S PIRO [CHROMAN - 4, 4 ' - IMIDAZOL] ONES AS BETA - SECRETASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217980-A1 AMLEXANOX ANALOGS GPR119, GLP1R, IRS1 MEN1 1944/4885KMT2A 2197/4885KEAP1 2101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.